These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 16801444)

  • 1. High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1.
    Imamichi T; Sinha T; Imamichi H; Zhang YM; Metcalf JA; Falloon J; Lane HC
    J Virol; 2000 Jan; 74(2):1023-8. PubMed ID: 10623768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance Trends of Antiretroviral Agents in People with Human Immunodeficiency Virus in Korea, 2012 - 2020.
    Oh SM; Bang J; Park SW; Lee E
    Infect Chemother; 2023 Sep; 55(3):328-336. PubMed ID: 37272233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
    Gregson J; Rhee SY; Datir R; Pillay D; Perno CF; Derache A; Shafer RS; Gupta RK
    J Infect Dis; 2020 Sep; 222(7):1108-1116. PubMed ID: 31774913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV Reverse Transcriptase and Protease Genes Variability Can Be a Biomarker Associated with HIV and Hepatitis B or C Coinfection.
    Cantão NM; Fogaça de Almeida L; Rodrigo Wolf I; Oliveira Almeida R; Alves de Almeida Cruz A; Nunes C; Barbosa AN; Valente GT; de Moura Campos Pardini MI; Grotto RMT
    Sci Rep; 2018 May; 8(1):8280. PubMed ID: 29844604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.
    Shafer RW; Schapiro JM
    AIDS Rev; 2008; 10(2):67-84. PubMed ID: 18615118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.
    Winters MA; Merigan TC
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2575-82. PubMed ID: 15980322
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients.
    Wirden M; Roquebert B; Derache A; Simon A; Duvivier C; Ghosn J; Dominguez S; Boutonnet V; Ait-Arkoub Z; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2553-6. PubMed ID: 16801444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 13. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.
    Frankel FA; Marchand B; Turner D; Götte M; Wainberg MA
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2657-64. PubMed ID: 15980333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
    Miranda LR; Götte M; Liang F; Kuritzkes DR
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.